ADMA Biologics (ADMA) - צמיחת רווחים בשנה הנוכחית

ADMA Biologics leads the plasma-derived medicines segment, investing heavily in antibody purification. The annual earnings per share growth indicator confirms this potential, with the metric currently standing at 24.50. A shortage of niche products allows the company to exercise pricing power and command premium prices. High margins and precise control over raw material collection ensure market confidence in the stable management.

This indicator captures the year-over-year dynamics of earnings per share, allowing for an assessment of net income generation rates relative to previous periods. For ADMA Biologics (ADMA), this snapshot of annual EPS change reflects the efficiency of its vertical integration—from proprietary plasma collection centers to the production of specialized immunodeficiency drugs—determining the business's investment attractiveness.